cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2019-5-117-127cardiovascular-2289Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMАналитический комплекс биохимических маркеров для доклинической диагностики и профилактики сердечно-сосудистых заболеванийAnalytical complex of biochemical markers for preclinical diagnosis and prevention of cardiovascular diseaseshttps://orcid.org/0000-0002-6108-3538ГумановаН. Г.GumanovaN. G.

Гуманова Надежда Георгиевна — кандидат биологических наук., ведуўій научный сотрудник отдела изучения биохимических маркеров хронических неинфекционных заболеваний.

Москва, Тел.: +7 (905) 771-18-36, (499) 553-68-51

Moscow

gumanova@mail.ruФГБУ «Национальный медицинский исследовательский центр профилактической медицины» Минзрава РоссииNational Medical Research Center for Preventive Medicine201930102019185117127Copyright © Гуманова Н.Г., 20192019Гуманова Н.Г.Gumanova N.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/2289

Благодаря достижениям мировой научной мысли, клинико-диагностические лаборатории, и диагностические центры, получили в распоряжение возможность анализа огромного количества биохимических маркеров различной природы, и их арсенал год от года пополняется. В предлагаемой статье рассматривается комплекс валидных биомаркеров, объединенных с целью биомедицинской доклинической диагностики и профилактики сердечно-сосудистых заболеваний. В качестве обоснования выбора именно этих биохимических маркеров приведены триггерные процессы, лежащие в основе развития сердечно-сосудистой патологии, с которыми ассоциированы избранные биохимические маркеры. Диагностический комплекс составлен на основе принципа “необходимого и достаточного”, с учетом финансовой целесообразности, и возможности измерения избранных маркеров в широкой сети клинико-диагностических центров или лабораторий. Обзор предназначен в помощь клиницистам с целью более детального понимания начальных, доклинических, стадий сердечно-сосудистых заболеваний, как самой распространенной причине смертности населения в России, а также для широкой аудитории, обучающейся или специализирующейся в области кардиологии.

Due to the achievements of world scientific thought, clinical diagnostic laboratories and diagnostic centers have been given the opportunity to analyze a huge number of biochemical markers of various nature, and their arsenal is replenished from year to year. This article discusses a complex of valid biomarkers, combined for the purpose of biomedical preclinical diagnosis and prevention of cardiovascular diseases. As a justification for the choice of these biochemical markers, we gave trigger processes that underlie the development of cardiovascular pathology, with which selected biochemical markers are associated. The diagnostic complex is based on the “necessity and sufficiency” principle, taking into account financial feasibility, and the ability to measure selected markers in a wide network of clinical diagnostic centers or laboratories. The review is intended to help clinicians with a view to a more detailed understanding of the initial, preclinical stages of cardiovascular diseases, as the most common cause of mortality in Russia, as well as for a wide audience studying or specializing in cardiology.

биохимические маркерысердечно-сосудистые заболеваниядиагностические тестывалидациядоклиническая диагностикаbiochemical markerscardiovascular diseasesdiagnostic testsvalidationpreclinical diagnosisнетReferencesAtkinson Jr AJ, Colburn WA, De Gruttola VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89-95. doi:10.1067/mcp.2001.113989.Atkinson Jr AJ, Colburn WA, De Gruttola VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89-95. doi:10.1067/mcp.2001.113989.Gluud C, Gluud LL. Evidence based diagnostics. BMJ. 2005;330(7493):724-6. doi:10.1136/bmj.3307493724.Gluud C, Gluud LL. Evidence based diagnostics. BMJ. 2005;330(7493):724-6. doi:10.1136/bmj.3307493724.Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem. 2010;56(2):177-85. doi: 10.1373/clinchem.2009.126706.Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem. 2010;56(2):177-85. doi: 10.1373/clinchem.2009.126706.Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 2015;4:180-3. doi:10.1016/j.redox.2015.01.002.Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 2015;4:180-3. doi:10.1016/j.redox.2015.01.002.Zhong S, Li L, Shen X, et al. An update on lipid oxidation and inflammation in cardiovascular diseases. Free Radic Biol Med. 2019; S0891-5849(19)30271-0. doi:10.1016/jReview. PubMed PMID: 30946962.Zhong S, Li L, Shen X, et al. An update on lipid oxidation and inflammation in cardiovascular diseases. Free Radic Biol Med. 2019; S0891-5849(19)30271-0. doi:10.1016/jReview. PubMed PMID: 30946962.Ross R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999;138(5):S419. PMID: 10539839.Ross R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999;138(5):S419. PMID: 10539839.Thiele JR, Zeller J, Bannasch H, et al. Targeting C-Reactive Protein in Inflammatory Disease by Preventing Conformational Changes. Mediators Inflamm. 2015;372432. doi:10.1155/2015/372432.Thiele JR, Zeller J, Bannasch H, et al. Targeting C-Reactive Protein in Inflammatory Disease by Preventing Conformational Changes. Mediators Inflamm. 2015;372432. doi:10.1155/2015/372432.Ristagno G, Fumagalli F, Bottazzi B, et al. Pentraxin 3 in Cardiovascular Disease. Front Immunol. 2019;10:823. doi:10.3389/fimmu.2019.00823. PubMed PMID: 31057548.Ristagno G, Fumagalli F, Bottazzi B, et al. Pentraxin 3 in Cardiovascular Disease. Front Immunol. 2019;10:823. doi:10.3389/fimmu.2019.00823. PubMed PMID: 31057548.Poredos P. C-reactive protein and the risk of cardiovascular morbidity and mortality. Vasa. 2017;46(2):77-8. doi:10.1024/0301-1526/a000602.Poredos P. C-reactive protein and the risk of cardiovascular morbidity and mortality. Vasa. 2017;46(2):77-8. doi:10.1024/0301-1526/a000602.Alexander CM, Landsman PB, Teutsch SM, et al. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52(5):1210-4. doi:10.2337/diabetes.52.5.1210.Alexander CM, Landsman PB, Teutsch SM, et al. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52(5):1210-4. doi:10.2337/diabetes.52.5.1210.Avan A, Tavakoly Sany SB, Ghayour-Mobarhan M, et al. Serum C-reactive protein in the prediction of cardiovascular diseases: Overview of the latest clinical studies and public health practice. J Cell Physiol. 2018;233(11):8508-25. doi:10.1002/jcp.26791.Avan A, Tavakoly Sany SB, Ghayour-Mobarhan M, et al. Serum C-reactive protein in the prediction of cardiovascular diseases: Overview of the latest clinical studies and public health practice. J Cell Physiol. 2018;233(11):8508-25. doi:10.1002/jcp.26791.Bacmeister L, Schwarzl M, Warnke S, et al. Inflammation and fibrosis in murine models of heart failure. Basic Res Cardiol. 2019;114(3): 19. doi:101007/s00395-019-0722-5.Bacmeister L, Schwarzl M, Warnke S, et al. Inflammation and fibrosis in murine models of heart failure. Basic Res Cardiol. 2019;114(3): 19. doi:101007/s00395-019-0722-5.Rupprecht HJ, Blankenberg S, Bickel C, et al. AutoGene Investigators. Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation. 2001;104(1):25-31. PMID: 11435333.Rupprecht HJ, Blankenberg S, Bickel C, et al. AutoGene Investigators. Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation. 2001;104(1):25-31. PMID: 11435333.Jolles S, Jordan SC, Orange JS, et al. Immunoglobulins: current understanding and future directions. Clin Exp Immunol. 2014;Suppl 1:163-8. doi:10.1111/cei.12555.Jolles S, Jordan SC, Orange JS, et al. Immunoglobulins: current understanding and future directions. Clin Exp Immunol. 2014;Suppl 1:163-8. doi:10.1111/cei.12555.Konukoglu D, Uzun H. Endothelial Dysfunction and Hypertension. Adv Exp Med Biol. 2017;956:511-40. doi:10.1007/5584_2016_90.Konukoglu D, Uzun H. Endothelial Dysfunction and Hypertension. Adv Exp Med Biol. 2017;956:511-40. doi:10.1007/5584_2016_90.Della Corte VD, Tuttolomondo A, Pecoraro R, et al. Inflammation, Endothelial Dysfunction and Arterial Stiffness as Therapeutic Targets in Cardiovascular Medicine. Curr Pharm Des. 2016; 22(30):4658-68. PMID: 27160758.Della Corte VD, Tuttolomondo A, Pecoraro R, et al. Inflammation, Endothelial Dysfunction and Arterial Stiffness as Therapeutic Targets in Cardiovascular Medicine. Curr Pharm Des. 2016; 22(30):4658-68. PMID: 27160758.Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation. 2003;107(3):398-404. PMID: 12551862.Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation. 2003;107(3):398-404. PMID: 12551862.Pokharel DR, Khadka D, Sigdel M, et al. Prevalence of metabolic syndrome in Nepalese type 2 diabetic patients according to WHO, NCEP ATP III, IDF and Harmonized criteria. J Diabetes Metab Disord. 2014;13(1):104. doi:10.1186/s40200-014-0104-3.Pokharel DR, Khadka D, Sigdel M, et al. Prevalence of metabolic syndrome in Nepalese type 2 diabetic patients according to WHO, NCEP ATP III, IDF and Harmonized criteria. J Diabetes Metab Disord. 2014;13(1):104. doi:10.1186/s40200-014-0104-3.Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U. S. Diabetes care. 2005;28(11):2745-9. PMID: 16249550.Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U. S. Diabetes care. 2005;28(11):2745-9. PMID: 16249550.Hanson RL, Imperatore G, Bennett PH, et al. Components of the “metabolic syndrome” and incidence of type 2 diabetes. Diabetes. 2002;51(10):3120-7 PMID: 12351457.Hanson RL, Imperatore G, Bennett PH, et al. Components of the “metabolic syndrome” and incidence of type 2 diabetes. Diabetes. 2002;51(10):3120-7 PMID: 12351457.Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108(4):414-9. doi:10.1161/01.CIR.0000080897.52664.94.Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108(4):414-9. doi:10.1161/01.CIR.0000080897.52664.94.Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245-50. doi:10.1161/01.CIR.0000140677.20606.0E.Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245-50. doi:10.1161/01.CIR.0000140677.20606.0E.Tao Z, Shi A, Zhao J. Epidemiological Perspectives of Diabetes. Cell Biochem Biophys. 2015;73(1):181-5. doi:10.1007/s12013-015-0598-4.Tao Z, Shi A, Zhao J. Epidemiological Perspectives of Diabetes. Cell Biochem Biophys. 2015;73(1):181-5. doi:10.1007/s12013-015-0598-4.Inoue H. Central insulin-mediated regulation of hepatic glucose production [Review]. Endocr J. 2016;63(1):1-7. doi:10.1507/endocrj.EJ15-0540.Inoue H. Central insulin-mediated regulation of hepatic glucose production [Review]. Endocr J. 2016;63(1):1-7. doi:10.1507/endocrj.EJ15-0540.Brown AE, Walker M. Genetics of Insulin Resistance and the Metabolic Syndrome. Curr Cardiol Rep. 2016;18(8):75. doi:10.1007/s11886-016-0755-4.Brown AE, Walker M. Genetics of Insulin Resistance and the Metabolic Syndrome. Curr Cardiol Rep. 2016;18(8):75. doi:10.1007/s11886-016-0755-4.Holman GD. Chemical biology probes of mammalian GLUT structure and function. Biochemical J. 2018;475(22):3511-34. doi:10.1042/BCJ20170677.Holman GD. Chemical biology probes of mammalian GLUT structure and function. Biochemical J. 2018;475(22):3511-34. doi:10.1042/BCJ20170677.Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9. PMID: 3899825.Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9. PMID: 3899825.Kim JK. Hyperinsulinemic-euglycemic clamp to assess insulin sensitivity in vivo. Methods Mol Biol. 2009;560:221-38, doi:10.1007/978-1-59745-448-3_15.Kim JK. Hyperinsulinemic-euglycemic clamp to assess insulin sensitivity in vivo. Methods Mol Biol. 2009;560:221-38, doi:10.1007/978-1-59745-448-3_15.Gayoso-Diz P, Otero-Gonzalez A, Rodriguez-Alvarez MX, et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord. 2013;13(1):47. doi:10.1186/1472-6823-13-47.Gayoso-Diz P, Otero-Gonzalez A, Rodriguez-Alvarez MX, et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord. 2013;13(1):47. doi:10.1186/1472-6823-13-47.Перова Н. В., Озерова И. Н., Александрович О. В. и др. Клиническое значение инсулинорезистентности при нормогликемии натощак. Кардиология. 2011;51(8):49-54.Perova NV, Ozerova IN, Aleksandrovich OV, et al. Clinical value of insulin resistance in fasting normoglycemia. Kardiologiia. 2011;51(8):49-54. (In Russ.)Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care. 1997;20(7):1087-92. PMID: 9203442.Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care. 1997;20(7):1087-92. PMID: 9203442.Helkin A, Stein JJ, Lin S, et al. Dyslipidemia Part 1-Review of Lipid Metabolism and Vascular Cell Physiology. Vasc Endovascular Surg. 2016;50(2):107-18. doi:10.1177/1538574416628654.Helkin A, Stein JJ, Lin S, et al. Dyslipidemia Part 1-Review of Lipid Metabolism and Vascular Cell Physiology. Vasc Endovascular Surg. 2016;50(2):107-18. doi:10.1177/1538574416628654.Rawla P, Sunkara T, Thandra KC, et al. Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies. Clinical Journal of Gastroenterology. 2018;11(6):441-8. doi:10.1007/s12328-018-0881-1.Rawla P, Sunkara T, Thandra KC, et al. Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies. Clinical Journal of Gastroenterology. 2018;11(6):441-8. doi:10.1007/s12328-018-0881-1.Alexopoulos AS, Qamar A, Hutchins K, et al. Triglycerides: Emerging Targets in Diabetes Care? Curr Diab Rep. 2019;19(4):13. doi:10.1007/s11892-019-1136-3. PMID: 30806837.Alexopoulos AS, Qamar A, Hutchins K, et al. Triglycerides: Emerging Targets in Diabetes Care? Curr Diab Rep. 2019;19(4):13. doi:10.1007/s11892-019-1136-3. PMID: 30806837.Roubille F, Sultan A, Huet F, et al. Is hypertriglyceridemia atherogenic? La Presse Medicale. 2018;47(9):757-63. doi:10.1016/j.lpm.2018.08.009.Roubille F, Sultan A, Huet F, et al. Is hypertriglyceridemia atherogenic? La Presse Medicale. 2018;47(9):757-63. doi:10.1016/j.lpm.2018.08.009.Inayat F, Zafar F, Baig AS, et al. Hypertriglyceridemic Pancreatitis Treated with Insulin Therapy: A Comparative Review of 34 Cases. Cureus. 2018;10(10). doi:10.7759/cureus.3501.Inayat F, Zafar F, Baig AS, et al. Hypertriglyceridemic Pancreatitis Treated with Insulin Therapy: A Comparative Review of 34 Cases. Cureus. 2018;10(10). doi:10.7759/cureus.3501.Mollazadeh H, Carbone F, Montecucco F. Oxidative burden in familial hypercholesterolemia. J Cell Physiol. 2018;233(8):5716-25. doi:10.1002/jcp.26466.Mollazadeh H, Carbone F, Montecucco F. Oxidative burden in familial hypercholesterolemia. J Cell Physiol. 2018;233(8):5716-25. doi:10.1002/jcp.26466.Getz G, Reardon C. Apoprotein E and Reverse Cholesterol Transport. Int J Mol Sci. 2018;19(11):3479. doi:10.3390/ijms19113479.Getz G, Reardon C. Apoprotein E and Reverse Cholesterol Transport. Int J Mol Sci. 2018;19(11):3479. doi:10.3390/ijms19113479.Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. The Lancet. 2007;370(9602):1829-39. PMID: 18061058.Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. The Lancet. 2007;370(9602):1829-39. PMID: 18061058.Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA. 1987;257(16):2176-80.Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA. 1987;257(16):2176-80.Rosenson RS. The High-Density Lipoprotein Puzzle: Why Classic Epidemiology, Genetic Epidemiology, and Clinical Trials Conflict? Arterioscler Thromb Vasc Biol. 2016;36(5):777-82. doi:10.1161/ATVBAHA.116.307024.Rosenson RS. The High-Density Lipoprotein Puzzle: Why Classic Epidemiology, Genetic Epidemiology, and Clinical Trials Conflict? Arterioscler Thromb Vasc Biol. 2016;36(5):777-82. doi:10.1161/ATVBAHA.116.307024.Chang JC. Hemostasis based on a novel 'two-path unifying theory' and classification of hemostatic disorders. Blood Coagul Fibrinolysis. 2018;29(7):573-84. doi:10.1097/MBC.0000000000000765.Chang JC. Hemostasis based on a novel 'two-path unifying theory' and classification of hemostatic disorders. Blood Coagul Fibrinolysis. 2018;29(7):573-84. doi:10.1097/MBC.0000000000000765.Asada Y, Yamashita A, Sato Y, et al. Thrombus Formation and Propagation in the Onset of Cardiovascular Events. J Atheroscler Thromb. 2018;25(8):653-64. doi:10.5551/jat.RV17022.Asada Y, Yamashita A, Sato Y, et al. Thrombus Formation and Propagation in the Onset of Cardiovascular Events. J Atheroscler Thromb. 2018;25(8):653-64. doi:10.5551/jat.RV17022.Bagot CN, Arya R. Virchow and his triad: a question of attribution. Br J Haematol. 2008;143(2):180-90. doi:10.1111/j.1365-2141.2008.07323.x.Bagot CN, Arya R. Virchow and his triad: a question of attribution. Br J Haematol. 2008;143(2):180-90. doi:10.1111/j.1365-2141.2008.07323.x.Krupiczojc MA, Scotton CJ, Chambers RC. Coagulation signaling following tissue injury: focus on the role of factor Xa. Int J Biochem Cell Biol. 2008;40(6-7):1228-37 doi:10.1016/j.biocel.2008.02.026.Krupiczojc MA, Scotton CJ, Chambers RC. Coagulation signaling following tissue injury: focus on the role of factor Xa. Int J Biochem Cell Biol. 2008;40(6-7):1228-37 doi:10.1016/j.biocel.2008.02.026.Chapin JC, Hajjar KA. Fibrinolysis and the control of blood coagulation. Blood Rev. 2015;29(1):17-24. doi:101016/j.blre.2014.09.003.Chapin JC, Hajjar KA. Fibrinolysis and the control of blood coagulation. Blood Rev. 2015;29(1):17-24. doi:101016/j.blre.2014.09.003.Thiebaut A M, Gauberti M, Ali C, et al. The role of plasminogen activators in stroke treatment: fibrinolysis and beyond. Lancet Neurol. 2018;17(12): 1121-32. doi:10.1016/S1474-4422(18)30323-5.Thiebaut A M, Gauberti M, Ali C, et al. The role of plasminogen activators in stroke treatment: fibrinolysis and beyond. Lancet Neurol. 2018;17(12): 1121-32. doi:10.1016/S1474-4422(18)30323-5.Nijenhuis VJ, Brouwer J, Sondergaard L, et al. Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation. Heart. 2019;heartjnl-2018-314313. doi:10.1136/heartjnl-2018-314313.Nijenhuis VJ, Brouwer J, Sondergaard L, et al. Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation. Heart. 2019;heartjnl-2018-314313. doi:10.1136/heartjnl-2018-314313.Danesh J, Lewington S, Thompson S G, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294(14):1799-809. doi:10.1001/jama.294.14.1799.Danesh J, Lewington S, Thompson S G, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294(14):1799-809. doi:10.1001/jama.294.14.1799.Bridge KI, Philippou H, Ariens RA. Clot properties and cardiovascular disease. Thromb Haemost. 2014;112(11):901-8. doi:10.1160/TH14-02-0184.Bridge KI, Philippou H, Ariëns RA. Clot properties and cardiovascular disease. Thromb Haemost. 2014;112(11):901-8. doi:10.1160/TH14-02-0184.

The authors declare that there are no conflicts of interest present.